Schizophrenia Clinical Trial
Official title:
Brain Myelination Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia
This study will determine the effects on brain myelination and cognition of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in first-episode schizophrenia subjects. The hypothesis being tested is that continual inhibition of enzymes such as glycogen synthetase kinase 3 provided by injectable paliperidone palmitate will promote myelination to a greater extent than oral risperidone.
Schizophrenia is a severely disabling brain disorder. People with schizophrenia often
experience hallucinations, delusions, thought disorders, and movement disorders. Proper
treatment of first-episode schizophrenia may increase the chances of controlling disease
progression on a long-term basis. People experiencing their first episode of schizophrenia
are more responsive to treatment than those with chronic schizophrenia, but are also more
susceptible to adverse treatment side effects. Atypical antipsychotic medications have been
shown to produce fewer extrapyramidal side effects than older "typical" antipsychotics. Oral
risperidone is an atypical antipsychotic medication that is very commonly used to control
the symptoms of schizophrenia. Adherence to prescribed oral medication continues to be a
major clinical issue.
This study will determine the effectiveness of oral risperidone versus a long-acting
injectable alternative, paliperidone palmitate, in improving brain myelination and cognitive
function in people with first-episode schizophrenia. Impact on brain myelination and
clinical symptoms will be examined to test the hypothesis that brain myelination changes
underlie one of the mechanisms of action of antipsychotics. This study will assess
biomarkers at baseline (pre randomization), 6 months, and end of "parent study"
participation.
Participants in the "parent" open label study will be randomly assigned to receive either
orally administered risperidone or long-acting paliperidone palmitate administered via
injection. Participants assigned to oral risperidone will receive medication in doses that
are determined to be optimal by the study psychiatrist. Participants assigned to long-acting
risperidone will receive an injection of paliperidone palmitate once every 4 weeks. Dosages
will be adjusted as necessary to achieve the optimal dosage. Following 2 to 3 months to
achieve outpatient oral risperidone dosage stabilization, the randomized medication
conditions will begin and participants will be monitored for 1 year. Parent study visits
will occur once weekly throughout the study. They will include psychiatrist monitoring of
medication response and side effects; group therapy meetings focused on everyday living
skills; family education about schizophrenia; and individual meetings with a case manager
for counseling and evaluations of schizophrenia symptoms, work recovery, and social
functioning.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |